UNSPSC 51183508: Metformin embonate

This classification denotes an anti-diabetic agent with the molecular formula C23H16O6.2C4H11N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V9AZJ7GJZ1, chemically known as 2-naphthalenecarboxylic acid, 4,4'-methylenebis(3-hydroxy-, compd. with n,n-dimethylimidodicarbonimidic diamide (1:2), but more generally known as metformin embonate, which bears US NIH Compound Identifier 62987.

European Medicines Agency schedules metformin embonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08831MIG. Most nations, for tariff purposes, schedule metformin embonate under HS 29252900. SMILES: CN(C)C(=N)NC(=N)N.CN(C)C(=N)NC(=N)N.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.

UNSPSC 51183508 Metformin embonate, a Commodity code, describes a specific pharmaceutical salt form of the antidiabetic agent metformin. State and local governments procure this formulation primarily through health departments, public health agencies, and correctional healthcare systems for treatment programs serving indigent or incarcerated populations. The drug is typically acquired via competitive bid or standing contract through state pharmaceutical cooperative purchasing vehicles or direct negotiation with manufacturers and authorized distributors. Metformin embonate is used in chronic disease management protocols within public health clinics, correctional facilities, and subsidized healthcare networks where cost containment and formulary standardization drive procurement decisions.

The source provides no recent state or local contract opportunities under this code. Without posted RFPs, RFQs, or ITBs identifying specific issuing bodies, response dates, or geographic activity, no characterization of current procurement volume, repeat buyers, or regional concentration can be supported. Vendors monitoring this code should track cooperative purchasing announcements from state pharmacy benefit managers and correctional healthcare procurement offices, as these bodies typically consolidate metformin formulation purchases across multiple agencies rather than issuing individual solicitations.